Goldman Sachs’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.74K | Sell |
767
-1,430
| -65% | -$15.1K | ﹤0.01% | 6495 |
|
|
2026
Q1 | $24.9K | Buy |
2,197
+399
| +22% | +$5.45K | ﹤0.01% | 6347 |
|
|
2025
Q4 | $23K | Sell |
1,798
-1,230
| -41% | -$18.9K | ﹤0.01% | 6336 |
|
|
2025
Q3 | $56.6K | Buy |
3,028
+688
| +29% | +$13.6K | ﹤0.01% | 6160 |
|
|
2025
Q2 | $59.9K | Sell |
2,340
-793
| -25% | -$15.9K | ﹤0.01% | 5888 |
|
|
2025
Q1 | $62.7K | Buy |
3,133
+1,876
| +149% | +$39.5K | ﹤0.01% | 5854 |
|
|
2024
Q4 | $22.9K | Buy |
+1,257
| New | +$24.7K | ﹤0.01% | 5889 |
|
|
2023
Q2 | – | Sell |
-768
| Closed | -$51.8K | – | 5797 |
|
|
2023
Q1 | $51.8K | Buy |
+768
| New | +$46.1K | ﹤0.01% | 5547 |
|
|
2022
Q4 | – | Sell |
-581
| Closed | -$16K | – | 6022 |
|
|
2022
Q3 | $16K | Sell |
581
-2,205
| -79% | -$86.1K | ﹤0.01% | 5967 |
|
|
2022
Q2 | $122K | Sell |
2,786
-12,158
| -81% | -$558K | ﹤0.01% | 5807 |
|
|
2022
Q1 | $954K | Buy |
14,944
+8,436
| +130% | +$604K | ﹤0.01% | 4857 |
|
|
2021
Q4 | $546K | Buy |
6,508
+2,155
| +50% | +$242K | ﹤0.01% | 5312 |
|
|
2021
Q3 | $707K | Sell |
4,353
-192
| -4% | -$31.2K | ﹤0.01% | 4987 |
|
|
2021
Q2 | $686K | Buy |
4,545
+1,132
| +33% | +$191K | ﹤0.01% | 5020 |
|
|
2021
Q1 | $593K | Sell |
3,413
-10,075
| -75% | -$1.92M | ﹤0.01% | 4994 |
|
|
2020
Q4 | $2.15M | Buy |
13,488
+3,548
| +36% | +$594K | ﹤0.01% | 3669 |
|
|
2020
Q3 | $1.59M | Buy |
9,940
+571
| +6% | +$103K | ﹤0.01% | 3737 |
|
|
2020
Q2 | $1.86M | Buy |
9,369
+5,585
| +148% | +$1.03M | ﹤0.01% | 3511 |
|
|
2020
Q1 | $585K | Buy |
3,784
+1,709
| +82% | +$173K | ﹤0.01% | 4116 |
|
|
2019
Q4 | $160K | Buy |
2,075
+1,399
| +207% | +$122K | ﹤0.01% | 4947 |
|
|
2019
Q3 | $68K | Buy |
676
+132
| +24% | +$15.4K | ﹤0.01% | 5014 |
|
|
2019
Q2 | $72K | Sell |
544
-152
| -22% | -$20.9K | ﹤0.01% | 4980 |
|
|
2019
Q1 | $105K | Sell |
696
-931
| -57% | -$145K | ﹤0.01% | 4922 |
|
|
2018
Q4 | $262K | Buy |
1,627
+451
| +38% | +$89.6K | ﹤0.01% | 4695 |
|
|
2018
Q3 | $303K | Buy |
1,176
+652
| +124% | +$163K | ﹤0.01% | 4708 |
|
|
2018
Q2 | $119K | Sell |
524
-1,577
| -75% | -$299K | ﹤0.01% | 5161 |
|
|
2018
Q1 | $296K | Buy |
2,101
+975
| +87% | +$147K | ﹤0.01% | 4789 |
|
|
2017
Q4 | $146K | Buy |
+1,126
| New | +$143K | ﹤0.01% | 5569 |
|
|
2016
Q1 | – | Sell |
-1,147
| Closed | -$128K | – | 7110 |
|
|
2015
Q4 | $128K | Buy |
1,147
+184
| +19% | +$25.1K | ﹤0.01% | 6037 |
|
|
2015
Q3 | $121K | Buy |
+963
| New | +$128K | ﹤0.01% | 6367 |
|
Other funds holding CTSO
CM
Goldman Sachs's CTSO Position: Q2 2026 in Review
Goldman Sachs reduced its Cytosorbents Corp (CTSO) stake by 65% in Q2 2026, selling an estimated $15.1K and leaving 767 shares worth $5.74K. The position accounts for ﹤0.01% of the portfolio, ranked #6495.
Goldman Sachs first reported a position in CTSO in Q3 2015 and has held it in 30 quarters since. The position peaked at $2.15M in Q4 2020. 47 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.
- Goldman Sachs held 767 shares of Cytosorbents Corp worth $5.74K as of Q2 2026.
- Goldman Sachs sold 1,430 Cytosorbents Corp shares in Q2 2026, an estimated $15.1K.
- Cytosorbents Corp made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6495 holding.
- Goldman Sachs first reported a position in Cytosorbents Corp in Q3 2015 and has held it in 30 quarters since.
- Goldman Sachs's Cytosorbents Corp position peaked at $2.15M in Q4 2020.
- 47 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.